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Efficient hemodialysis requires establishing a permanent
stable vascular access. Our study was designed to evaluate
formaldehyde-fixed arterial allografts as hemodialysis access
for end-stage renal disease. Various parameters were
determined for 68 formaldehyde-fixed, cadaver-derived
allografts transplanted into 43 hemodialysis patients. The
sources of the allografts were determined to be free of
cytomegalovirus, hepatitis B and hepatitis C, and HIV
infections. These allografts were monitored for rejection,
blood flow, patency rates, and complications. Overall,
antigenicity of the allografts was reduced after formaldehyde
fixation with no acute rejection. The mean access blood flow
was 6967282 ml with reasonable primary and secondary
patency rates even after 3 years. Allograft intimal
hyperplasia, determined by immunohistochemistry, was
evident as the proliferation of smooth muscle-like cells
expressing actin but cells not expressing the endothelial
markers von Willebrand factor or CD34. The incidence of
thrombus formation was about 37% after allograft transplant
with other limited complications of pseudoaneurysms and
local infection. Our results support the clinical use of
formaldehyde-fixed arterial allografts for hemodialysis
access.
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Patients with irreversible end-stage renal disease (ESRD) are
treated with renal replacement therapies such as hemodialysis
(HD) using established permanent vascular access. The
typical vascular access includes autogenous arteriovenous
fistulas (AVFs) and heterotope AVF such as polytetrafluor-
oethylene (PTFE) grafts. The use of autologous vascular
grafts has been limited due to its availability. The PTFE grafts
have been widely utilized in elderly or diabetic patients with
poor peripheral blood vascular conditions.1,2 However, the
complications such as recurrent stenosis, thrombosis, infec-
tion, and pseudoaneurysm are major barriers to its long-term
patency due to the lack of vascular endothelial cells (ECs),
and the underlining mechanisms of stenosis are graft intimal
hyperplasia.1,3,4 Additionally, the cost of PTFE grafts has
remained as a major concern in current Chinese market and
the average price for PTFE grafts has remained above $1250 a
piece.
It has been proposed that vascular grafts obtained from
animals and humans be used as an alternative to PTFE.5,6
Although bovine heterovascular grafts have been utilized, and
produced comparable results to PTFE, the graft rupture-
associated, life-threatening hemorrhage has limited its
clinical application.7,8 Previous investigations have focused
on the use of vascular allografts such as cryopreserved
vascular allografts as long-term HD access for patients with
ESRD.9 Deep hypothermia (1961C)-preserved vascular
allografts have shown viable, intact EC layer within grafts at
the time of transplantation, an important factor for
prevention of thrombosis.10,11 However, Solanes et al.12 have
demonstrated in an in vivo porcine model that the
immunogenicity of vascular allografts was not reduced by
cryopreservation, and the use of allografts as vascular access
failed due to allograft rejection that was mediated by T cells
and macrophages . Additionally, clinical study using
cryopreserved cadaveric femoral vein allografts as HD access
has revealed increased pseudoaneurysms when compared
with PTFE.13 Indeed, allosensitization characterized by
increased panel-reactive antibody has been induced by
cadaveric vein allografts when used as HD access in
nonimmunosuppressed patients.14
It is clear that the cryopreserved vascular allografts
maintain immunogenicity, and the vascular allograft rejec-
tion and allosensitization minimize the potential clinical
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application for the use of cryopreserved fresh vascular
allografts as HD access. However, it has been unknown
whether formaldehyde-prepared arterial allografts can be
rejected after transplantation, and used as vascular access for
long-term HD in patients with ESRD. We have performed
this clinical study to utilize cadaveric donor femoral arteries
prepared by formaldehyde fixation to establish an AVF as
long-term HD access. The allograft rejection, blood flow,
patency rates, and complications were closely monitored, and
the immunohistological characters of vascular allograft were
evaluated after allograft failure. This study clearly demon-
strated reduced allograft antigenicity following formaldehyde
fixation, and absence of acute allograft rejection after
transplants. The blood flow and patency rates were satisfied
with very limited complications when used as HD access.
Intimal hyperplasia of vascular allografts was characterized by
proliferation of smooth muscle cell (SMC)-like cells express-
ing actin but not von Willebrand factor (vWF) and CD34.
RESULTS
Formaldehyde-fixed vascular allografts lack alloantigenicity
To verify the antigenicity of arterial allografts, the antisera
were obtained from animals immunized with alloantigen
preparation from formaldehyde-fixed or -unfixed arterial
allografts. The antigenicity of allografts was assessed by
double diffusion in two dimensions. A line of precipitation
was revealed during interaction between antisera and
alloantigen preparations from unfixed arterial allografts. In
contrast, double diffusion in two dimensions did not
demonstrate any precipitation when alloantigens isolated
from formaldehyde-fixed allografts were used to interact with
antisera (Figure 1).
Absence of acute allograft rejection after transplantation
All patients receiving formaldehyde-fixed arterial allografts
for HD access were closely monitored for signs of hyperacute
and acute allograft rejection. The majority of patients
received ABO-mismatched vascular allografts. However,
fever, local edema, and acute thrombosis were not observed
in all patients following allograft transplantation. Tissue
samples were collected when allograft failure occurred, and
evaluated microscopically to exclude allograft rejection as the
cause for graft failure. As shown in Figure 2, arterial allografts
demonstrated normal arterial structures with thrombi but
without lymphocyte infiltration.
Patency of arterial allografts used as HD access
Forty-three patients received 68 formaldehyde-fixed arterial
allografts that were used as HD access. The primary patency,
defined as the interval from transplantation to any interven-
tion procedures to maintain its patency, and secondary
patency, defined as the interval from transplantation to
allograft failure including any interventions to maintain or
reestablish patency,15 were monitored closely after transplan-
tation and intervention. The initial color Doppler ultrasound
examination was carried out to evaluate the blood flow of
allografts as HD access at 2-week post-transplantation, and
demonstrated normal intimas of arterial allografts without
stenosis and thrombosis. The volume of blood flow ranged
from 410 to 1280 ml/min (6967282 ml/min) at 1-month
post-transplantation. As shown in Figure 3, the primary
patency rates at 3, 6 months, 1, 2, and 3 years were 9074,
8574, 7476, 5377, and 4277%, respectively. The median
patency rate was 28.06 months, and the secondary patency
rates were 9573, 9374, 9075, 7377, and 6279%. The
median patency rate was 141 months with satisfied blood
flow when used as HD access. The average bleeding time after
HD procedures was 8.271.6 min without development of
hematoma.
Clinical data of arterial allograft as HD access
Table 1 summarizes dialysis adequacy, hemoglobin, erythro-
poietin dose, C-reactive protein levels, dry weight, blood
flow, and Kt/V (The fraction of the volume cleared from
urea) values in these patients before and after implantation of
a b
Figure 1 | The antigenicity of allografts was determined by
double diffusion in two dimensions. Alloantigens were diluted to
1:4 with normal saline and added to center well of agarose gel.
Normal saline was added to top wells and used as controls. Antisera
were added to other wells at dilution of 1:2 (left), 1:4 (bottom), and
1:8 (right). Reaction was carried out at 371C overnight. (a) Alloantigen
preparations from unfixed arterial allografts interacted with specific
antisera, resulting in lines of precipitation but not normal saline. (b) In
contrast, double diffusion in two dimensions did not demonstrate
any precipitation when alloantigens isolated from formaldehyde-
fixed allografts were used to interact with specific antisera.
Figure 2 | Histology of arterial allograft sample collected 30 days
after transplantation. Hematoxylin and eosin stain staining showed
normal arterial structures with thrombi but without lymphocyte
infiltration (original magnification  200).
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fixed arterial allografts (at 3, 6, 12, and 24 months). Dialysis
adequacy was determined by Kt/V, which was calculated by
second-generation logarithm formula.
Complications of arterial allograft as HD access
The incidence of thrombosis was 37.3% after arterial allograft
transplantation (25 of the 68 transplants), and the time for its
development ranged from 30 to 1804 days post-transplanta-
tion. The thrombectomy with Fogarty catheter reestablished
patency of arterial allografts effectively. Other complications
included pseudoaneurysms (n¼ 2), which developed at post-
transplantation days 682 and 1487, local infection at
puncture site (n¼ 1) occurring at post-transplantation day
428, and moderate hematoma (n¼ 3) within 1 week of post-
transplantation. Six patients died without direct correlation
with arterial allograft transplantation, and the causes of death
after transplantation were cardiovascular disease (n¼ 2),
cerebral accident (n¼ 2), hepatic cirrhosis (n¼ 1), and road
accident (n¼ 1). Aeroembolism and Steal syndrome were not
observed in all patients after allograft transplantation.
All recipients have had screening test routinely for
cytomegalovirus, hepatitis B and hepatitis C, and HIV before
vascular allograft transplants, and repeated screening tests at
1, 3, 6, and 12 months post-transplantation. Two recipients
(4.65%) were positive for hepatitis B, and five patients
(11.63%) were positive for hepatitis C before vascular
allotransplantation. There were no new cases identified for
cytomegalovirus, hepatitis B and hepatitis C, and HIV 12
months after transplantation.
Histological and immunohistological studies
The histological features of formaldehyde-fixed arterial
allografts were first evaluated microscopically before arterial
allograft transplantation. The main structures of femoral
artery were normal and well preserved with intact arterial
vascular EC layers, collagenous fibers, and elastic fibers
(Figure 4a). The features of arterial arthrosclerosis were not
revealed in allografts (data not shown). The degenerescence,
calcification, and infected false aneurysm were not revealed.
The arterial allografts were collected at time of throm-
bectomy or removal of failed allografts, and evaluated by
histological and immunohistological studies. As shown in
Figure 4b, the significant proliferation of allograft intima was
observed with complete histological structures when com-
pared with normal formaldehyde-fixed allografts. The
lymphocyte and monocyte infiltration was not revealed.
The proliferative intima was composed of SMC-like cells. The
elastic fibers of allografts were positive for Weigert staining,
and structures of fibers were normal when compared with
normal formaldehyde-fixed allografts (Figure 4c). We did not
find degenerescence and calcification developed in allografts.
Immunohistological staining of arterial allografts collected
after graft failure demonstrated that the allograft ECs were
positive staining for vWF and CD34, and proliferative SMC-
like cells stained negative for vWF and CD34 (Figure 4d–e).
Normal formaldehyde-fixed allografts stained positive for
actin on SMC (data not shown). In contrast, the proliferative
SMC-like cells of allograft intima were also stained positive
for actin antigen (Figure 4f).
DISCUSSION
HD using established permanent vascular access has been
widely used as renal replacement therapy for ESRD patients
with poor peripheral blood vessels. Although autologous
vascular grafts are preferred the availability of such grafts is
limited. The clinical studies have focused on the use of
cryopreserved vascular allografts obtained from humans as
Primary patency
Pa
te
nc
y 
ra
te
 (%
)
Secondary patency
100
80
60
40
20
0
0.0
0
12
.00
24
.00
36
.00
48
.00
60
.00
72
.00
84
.00
96
.00
10
8.0
0
12
0.0
0
13
2.0
0
14
4.0
0
15
6.0
0
Months
Primary
Secondary
68 47 29
395368
15
25 16
4 1 0
8 6 4 2 2 1 1 0 0
Figure 3 | Primary and secondary patency rates after arterial
allograft transplantation.
Table 1 | Hemoglobin, EPO dose, CRP levels, dry weight, blood flow in HD, and Kt/V changes of formaldehyde-fixed arterial
allograft transplants AVF
0 month 3 months 6 months 12 months 24 months
Hemoglobin (g/l) 93.879.1 94.9710.2 95.879.5 97.577.3 100.978.1
EPO dose (U/kg wt) 114731 99731 93727 90725 86719
CRP levels (mg/dl) 6.173.6 5.974.2 6.272.9 6.672.9 6.972.2
Dry weight (kg) 60.277.9 60.578.7 61.178.2 62.279.5 61.179.9
Blood flow in HD 239732 248733 236731 241730
Kt/V 1.3270.19 1.3470.21 1.3570.19 1.3770.20
AVF, arteriovenous fistula; CRP, C-reactive protein; EPO, erythropoietin; HD, hemodialysis.
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alternative to PTFE.5–7 However, viable ECs of vascular
allografts express HLA class I antigens and upregulate HLA
class II on their activation leading to allograft rejection
mediated by T cells and monocytes. Additionally, these
cryopreserved vascular allografts induce allosensitization in
nonimmunosuppressed patients with increased panel-reac-
tive antibody.14 The initial focus of this study was to
determine the alloantigenicity of formaldehyde-fixed arterial
allografts. Our in vivo study demonstrated first that unfixed
fresh arterial allografts induced antibody production in
rabbits that was specific to alloantigens after immunization.
In contrast, rabbits immunized with antigens prepared from
formaldehyde-fixed arterial allografts failed to produce
specific antibody to alloantigens, suggesting that preparation
of arterial allografts by formaldehyde fixation can effectively
eliminate alloantigens.
The formaldehyde-fixed arterial allografts were trans-
planted into the patients without available vascular condi-
tions, and these patients did not receive any
immunosuppressive therapy. The majority of patients
received ABO-mismatched vascular allografts. In fact, the
hyperacute and acute allograft rejection were absence in all
patients following transplantation. The histological evalua-
tion of allografts revealed the absence of lymphocyte and
monocyte infiltrates. These findings support our rationale to
utilize formaldehyde-fixed arterial allograft as HD access in
patients with ESRD.
Previous studies using 6-mm PTFE grafts as HD access
have demonstrated 1- and 2-year primary patency rates at 50
and 25%,16 respectively. The formaldehyde-fixed arterial
allografts were used as HD access in this study and the
blood flow of arterial allografts was satisfied. The major
limitation for the current study using arterial allografts as HD
access is the lack of control population due to very high costs
of PTFE grafts in China. Indeed, our study demonstrated
1-year primary patency rate at 7476%, and 3-year at
4277%, and these data appeared to be better than previously
published results using cryopreserved vascular grafts as HD
access.13,17 The secondary patency rates at 1 and 3 years were
9075 and 6279%, and these results were comparable with
cryopreserved vascular grafts reported previously.13,17
A significant observation of this study was the low rate of
pseudoaneurysms formation (2.9%) when compared to 20%
of those reported previously.13 Additionally, allograft trans-
plantation-related infection occurred in only one patient
when compared to cryopreserved vascular grafts,13 but well
below infection rates in patients who received PTFE
grafts.13,18 Other complications such as Steal syndrome were
not observed in these patients.
Previous study has demonstrated that the rate of
aneurysm in patients who received cryopreserved femoral
vein allografts was significantly higher than PTFE grafts.13
Therefore, we have used arterial allografts to establish HD
access. Indeed, it is still not clear whether the use of fixed or
denaturized vein allografts can achieve similar outcome when
compared with fixed arterial allografts. We are currently
conducting a new study to investigate the use of fixed vein
allografts as HD access in our patients.
The stenosis of vascular allografts due to intimal
hyperplasia accompanied by development of thrombosis
was observed at the end of arterial anastomosis in 37.3% of
transplants. The thrombectomy and reanastomosis can
effectively reestablish patency of arterial allografts as HD
access. Allograft intimal hyperplasia was characterized by
proliferation of SMC-like cells with complete arterial
structures and EC monolayer but without infiltration of
lymphocytes and monocytes. The expression of vWF and
CD34 was noted in these allograft ECs but not in the SMC-
like cells. The most important observation was that the
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Figure 4 | Histology and immunohistology of normal
formaldehyde-fixed arterial allografts and transplanted
allografts. (a) Hematoxylin and eosin stain staining of normal arterial
allograft before transplantation demonstrated normal arterial
structures with well-preserved intact arterial vascular ECs, elastic
fibers, and SMC (original magnification  200). (b) Hematoxylin and
eosin stain staining of arterial allograft collected 6 month after
transplantation demonstrated significant allograft intima proliferation
without lymphocyte infiltration (original magnification  200).
(c) Elastic fibers of arterial allografts were positive for Weigert,
6 months after transplantation, and the main structures of fibers
appeared normal (original magnification  100). (d) The proliferative
intima of arterial allograft 6 month after transplantation
demonstrated positive staining for vWF on the surface, and the vWF
staining was negative on proliferative SMC (original magnification
 100). (e) Surfaces of proliferative intima were stained positive for
CD34 (original magnification  200), and proliferative SMC was
stained negative for CD34, 6 months after transplantation. (f) Arterial
allograft collected 6 months after transplantation demonstrated
positive staining for actin antigen on proliferative cells of allograft
intima as well as SMC of arterial wall (original magnification  200).
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proliferative SMC-like cells express actin antigen as deter-
mined by immunohistological staining, suggesting the
possibility of migration of SMC from native artery to
transplant arterial allografts at the site of anastomosis.
The other benefit of utilizing formaldehyde-fixed arterial
allografts is its cost saving. The average price for PTFE grafts
are more than $1250 a piece. It is much more expensive than
formaldehyde-fixed arterial allografts, which are approxi-
mately $250 a piece. Additionally, formaldehyde-fixed arterial
allografts are easy to prepare and preserve. These benefits
have led these arterial allografts more acceptable currently for
both patients and surgeons in China.
We conclude here that formaldehyde fixation can
effectively reduce alloantigenicity of arterial allografts, and
hyperacute and acute allograft rejection can be avoidable
following vascular allograft transplantation for HD access.
The use of formaldehyde-fixed arterial grafts as AVF access in
ESRD patients demonstrates satisfied blood flow and patency
rates with limited complications in short- and mid-term HD.
The main structures of arterial allografts were well preserved
by formaldehyde fixation. Intimal hyperplasia of vascular
allografts is characterized by SMC-like cells that express actin,
suggesting the possibility of migration of SMC from native
artery to transplant arterial allografts. Our results suggest the
possibility of using formaldehyde fixed-arterial grafts as an
alternative to PTFE grafts for ESRD patients with poor
vascular access. A long-term follow-up is needed to
determine the advantages of this arterial allograft in HD
patients.
MATERIALS AND METHODS
This was a prospective and nonrandomized study to evaluate
formaldehyde-fixed arterial allografts as long-term HD access in
patients with ESRD. This study was conducted in accordance with
the Declaration of Helsinki (1996) with an approved protocol from
the University Ethics Committee and the Internal Review Board of
the University Hospital. The vascular allografts were collected from
cadaver donors of serious trauma and brain tumor. The consent
form signed by donor families was obtained followed by tissue
collection with permission from the University Hospital Internal
Review Board.
Collection, preparation, and preservation of vascular allo-
grafts
The selection of cadaver donor was based on thorough evaluation to
exclude the presence of infectious diseases, vascular diseases, and
malignant tumors (except brain tumor). We have routinely
performed laboratory screening tests for viral status including
cytomegalovirus, hepatitis B and hepatitis C, and HIV on all donors
before procurement of vascular grafts. Vascular allografts from
virus-negative donors were harvested and processed for vascular
allotransplantation. The donor age ranged from 23 to 45 years, and
femoral arteries were collected under aseptic surgical procedures,
and allografts were washed with sterile normal saline followed by
removal of connective tissue. Allografts were fixed with 20%
formaldehyde (Wuxi Suqiang Chemical Industry Company, Jiangsu,
China) at room temperature for 4 h after extensive washing with
sterile normal saline. Formaldehyde-fixed allografts were washed
three times with sterile normal saline, and then prepared with 95%
alcohol (Wuxi Suqiang Chemical Industry Company) at room
temperature for 72 h to remove fat, followed by preservation in 75%
alcohol at 41C until transplantation.
Assessment of vascular allograft antigenicity
Antigens were prepared from fresh allografts and formaldehyde-
fixed allografts according to the methods described by Nolly.19
Allograft antigens were premixed with Complete Freund’s adjuvant
(Sigma Chemical Company, St Louis, MO, USA). Twelve New
Zealand white rabbits, 2–2.5 kg, were immunized by intradermal
injection of antigens from fresh allograft (n¼ 6) or formaldehyde-
fixed allografts (n¼ 6) at 0.5 mg/kg, and booster immunization with
antigens at 0.5 mg/kg diluted in normal saline was carried out
intravenously via the marginal ear vein on days 14 and 21. Rabbit
blood samples were collected 1 week after final booster immuniza-
tion. The blood was centrifuged at 2000 r.p.m. for 30 min at 41C and
the serum was collected, and heat-treated at 561C for 30 min to
inactivate complement. Antisera were then centrifuged at
2000 r.p.m. for 10 min and filtered with 0.22 mm sterile filter. The
antigenicity of allografts was evaluated by double diffusion in two
dimensions. Briefly, agarose gel (2% agar in barbitone buffer) was
prepared on slides, and wells were created at a diameter of 3 mm.
Allograft antigens and antisera were added into each well, and slides
were incubated at 371C overnight to allow migration toward each
other. A line of precipitation was identified as a positive reaction
where the two reactions met.
Patient selection
Forty-three patients with ESRD requiring chronic HD received 68
formaldehyde-fixed arterial allograft transplants between October
1996 and May 2006. The allografts were used as HD access 3 weeks
after transplants. The selection of patients for vascular allografts was
based on (1) poor vascular condition of forearm including tenuity
vein or arteriosclerosis (n¼ 21), (2) multiple failure of internal AVF
procedures, unavailability of native vessels to establish HD access
(n¼ 19), (3) pseudoaneurysm of internal AVF (n¼ 2), and (4)
blood flow of autogenous AVF was not satisfied as access for HD
(n¼ 1). Table 2 summarizes the demographics of patients who
received vascular allografts regarding their age, sex, and etiology of
primary renal diseases.
Vascular allografts and transplantation
The preservation of vascular allografts ranged from 2 to 15 months
(mean: 6.4574.20 months). The length of vascular allografts was
23.2073.50 cm and mean diameter varied from 0.5370.16 cm. The
Table 2 | Primary disease of ESRD
No. of cases %
Male 28 65.1
Female 15 34.9
Age (years) 59.51710.71
Chronic GN 19 44.2
Diabetic nephropathy 11 25.6
Hypertensive arteriolonephrosclerosis 9 20.9
Chronic pyelonephritis 1 2.3
Hepatitis B virus-associated membranous GN 1 2.3
Henoch–Schonlein purpura nephritis 1 2.3
Nephrectomy 1 2.3
ESRD, end-stage renal disease, GN, glomerulonephritis.
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transplantation sites were selected in forearm both in craspedo-
drome (n¼ 53) and U-pass-b (n¼ 14), one patient received the
U-pass-b between femoral artery and femoral vein (n¼ 1). The
vascular allograft transplants were performed under local anesthesia,
and perioperative antibiotics (cefazolin, 5.0 g/day) were used in all
patients to prevent infections. The antibiotics were discontinued
48 h postoperatively. Twenty-seven of the 43 patients received single
arterial allograft transplant. Ten of the 43 patients received
secondary allografts after failure of initial allografts. Three patients
received third vascular allograft after failure of previous two
transplants, and three patients received fourth vascular allografts
when their third allograft failed. There were no attempts to match
ABO blood type as well as HLA typing between arterial allograft
donors and recipients. Indeed, 31 patients received ABO-mis-
matched vascular allografts. All patients did not receive any
immunosuppressive therapy before and after transplantation.
Monitor of allografts and treatment of complications
Allografts were monitored closely for patency and complications
after allotransplantation. The blood flow of allografts was evaluated
by Doppler ultrasound (HDI-5000, 5–12MHZ, ATL, Indianapolis,
IN, USA) at 1 month post-transplantation. The AVF was utilized as
HD access 3 weeks after allograft transplantation, and the bleeding
time of puncher site was recorded after each HD procedure.
Pathological and immunohistological studies of allografts
Allograft samples were collected during thrombectomy or removal
of allografts after graft failure, and tissue samples were fixed in 10%
neutral-buffered formalin, and then paraffin embedded for histo-
logical and immunohistological evaluation. Fixed tissue sections
were stained with hematoxylin and eosin stain, and evaluated
microscopically. Immunohistochemical staining was carried out as
described previously.20 Briefly, tissue sections (4mm) were depar-
affinized and washed three times with distilled water followed by
incubation with 3% H2O2 at room temperature for 10 min to
eliminate enzymatic active of endogenous peroxidase. The retrieval
of CD34 and vWF antigens was achieved by incubation of sections
with trypsin for 15 min, and then washed three times with distilled
water. Sections were incubated with blocking buffer containing 10%
normal goat serum at room temperature for 15 min to reduce
nonspecific antibody binding. Sections were incubated with primary
monoclonal mouse anti-human antibodies specific to vWF, CD34,
and actin (ZYMED Company, San Diego, CA, USA) at 371C for 2 h
followed by extensive washing with Ca2þ and Mg2þ -free phos-
phate-buffered saline (Gibco, Grand Island, NY, USA). Sections were
incubated with biotin-labeled secondary goat anti-mouse rabbit
polyclonal antibody at 371C for 30 min, and then washed three times
with phosphate-buffered saline and stained with horseradish
enzyme-labeled streptomycin antibiotin and a chromagen solution
of 3,30-diaminobenzidine. Slides were coverslipped and reviewed
microscopically.
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